OBJECTIVE: The aim of this study was to provide a comprehensive clinicopathological analysis of oral Kaposi sarcoma (KS) cases and examine its relationship with HIV-related immunosuppression. STUDY DESIGN: Paraffin-embedded tissue blocks of patients microscopically diagnosed with oral KS were retrieved from three oral and maxillofacial pathology files. Data including clinical, laboratory, microscopic and immunohistochemical findings and treatment employed were retrieved. RESULTS: A total of 40 patients with an average age of 33.5 years, with a male predominance were retrieved. The most common site was the hard palate, followed by the gingiva. Oral lesions were the first sign of KS in 57.5% of cases. Laboratory findings revealed an average viral load of 185,416 copies/mL, a mean CD4 count of 159.95 cells/mm³, CD8 count of 1062.65 cells/mm³, and a CD4/CD8 ratio of 0.148 cells/mm³. Histopathology showed spindle-shaped cell proliferation, vascular channels, hemorrhage, and hemosiderin deposits. Immunohistochemistry confirmed positivity for CD34, CD31, and HHV-8. Patients were treated with highly active antiretroviral therapy (HAART) (75%), and chemotherapy (47.5%). CONCLUSION: Oral KS remains a significant marker of HIV-related immunosuppression, especially where the burden of disease remains substantial. While HAART plays a critical role in managing KS, combined chemotherapy is often necessary for advanced cases.